Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Olive

Showing results (261-270 of 276) with videos related to

Pageof 28
Sort By:
Cancer Research|June 28, 2023
CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast CancerStéphane Fattori, Aude Le Roy, Jemila Houacine, et al.
Cancer Immunology Research|July 8, 2025
Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti-PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast CancerStéphane Fattori, Laurent Gorvel, Marie-Sarah Rouvière, et al.
Science Translational Medicine|October 20, 2021
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune responseAude De Gassart, Kieu-Suong Le, Patrick Brune, et al.
Nature Communications|June 30, 2022
Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editingSumin Jo, Shipra Das, Alan Williams, et al.
BMC Cancer|May 13, 2023
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancerDaniele Fanale, Chiara Brando, Lidia Rita Corsini, et al.
Blood Advances|May 24, 2024
Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemiaAnne-Charlotte Le Floch, Florence Orlanducci, Marie-Christine Béné, et al.
Blood|July 16, 2005
CD molecules 2005: human cell differentiation moleculesHeddy Zola, Bernadette Swart, Ian Nicholson, et al.
Cell Reports|September 26, 2024
BTN2A1 targeting reprograms M2-like macrophages and TAMs via SYK and MAPK signalingClément Kerneur, Etienne Foucher, Jaime Guillén Casas, et al.
Frontiers in Immunology|June 15, 2017
Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid LeukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
The Journal of Clinical Investigation|June 3, 2020
γ9δ2T cell diversity and the receptor interface with tumor cellsAnna Vyborova, Dennis X Beringer, Domenico Fasci, et al.
Pageof 28

Showing results (261-270 of 276) with videos related to

Sort By:
Pageof 28
Cancer Research|June 28, 2023
CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast CancerStéphane Fattori, Aude Le Roy, Jemila Houacine, et al.
Cancer Immunology Research|July 8, 2025
Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti-PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast CancerStéphane Fattori, Laurent Gorvel, Marie-Sarah Rouvière, et al.
Science Translational Medicine|October 20, 2021
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune responseAude De Gassart, Kieu-Suong Le, Patrick Brune, et al.
Nature Communications|June 30, 2022
Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editingSumin Jo, Shipra Das, Alan Williams, et al.
BMC Cancer|May 13, 2023
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancerDaniele Fanale, Chiara Brando, Lidia Rita Corsini, et al.
Blood Advances|May 24, 2024
Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemiaAnne-Charlotte Le Floch, Florence Orlanducci, Marie-Christine Béné, et al.
Blood|July 16, 2005
CD molecules 2005: human cell differentiation moleculesHeddy Zola, Bernadette Swart, Ian Nicholson, et al.
Cell Reports|September 26, 2024
BTN2A1 targeting reprograms M2-like macrophages and TAMs via SYK and MAPK signalingClément Kerneur, Etienne Foucher, Jaime Guillén Casas, et al.
Frontiers in Immunology|June 15, 2017
Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid LeukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
The Journal of Clinical Investigation|June 3, 2020
γ9δ2T cell diversity and the receptor interface with tumor cellsAnna Vyborova, Dennis X Beringer, Domenico Fasci, et al.
Pageof 28